6th Jun 2006 07:00
For immediate release 6 June 2006 LiDCO Group plc Product Registration in Switzerland LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, ispleased to announce approval by the Swiss regulatory body Swissmedic for theLiDCO System lithium chloride injection. Lithium chloride is used inconjunction with the LiDCOplus Monitor to provide an absolute measure of apatient's cardiac output. This latest registration now provides LiDCO with fullmarketing approval to sell into 14 European countries.Terry O'Brien, Chief Executive of LiDCO, stated: "Switzerland is Europe'shighest per capita income country, has one of the best health care systems inthe world and spends 11% of the gross national product on health care. Weexpect that our distribution partner Homedica will establish Switzerland as animportant market for LiDCO's products."For further information please contact:LiDCO Group PlcTerry O'Brien - Chief ExecutiveHugh McGarel-Groves - Finance DirectorTel: +44 (0)20 7749 1500Buchanan CommunicationsTim Anderson, Mary-Jane JohnsonTel: +44 (0)20 7466 5000Panmure GordonGrant Harrison, Aubrey Powell, Andrew Collins, Katherine RoeTel: +44 (0)20 7459 3600Notes to EditorsAbout LiDCO PlcLiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base.The Company's manufacturing facility is in Hoxton, London and its currentproducts are:* LiDCOplus and PulseCO monitors: computer-based platforms for displaying arange of real-time, continuous hemodynamic parameters including cardiac output,oxygen delivery and fluid volume;* LiDCO disposables: used in conjunction with the LiDCOplus Monitor toaccurately determine cardiac output in a minimally-invasive manner.Distribution Network:The Company has now achieved registration of its products in 17 markets inEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors.ENDLIDCO GROUP PLCRelated Shares:
LID.L